GPCR Inhibition in Treating Lymphoma

G protein-coupled receptors (GPCRs) are important classes of cell surface receptors involved in multiple physiological functions. Aberrant expression, upregulation, and mutation of GPCR signaling pathways are frequent in many types of cancers, promoting hyperproliferation, angiogenesis, and metastasis. Recent studies showed that alterations of GPCRs are involved in different lymphoma types. Herein, we review the synthetic strategies to obtain GPCR inhibitors, focusing on CXCR4 inhibitors which represent most of the GPCR inhibitors available in the market or under preclinical investigations for these diseases.

Automated summary

This article reviews the synthetic strategies for obtaining G protein-coupled receptor inhibitors, with a focus on CXCR4 inhibitors used in the treatment of lymphomas. Studies have found that alterations in GPCRs are associated with various types of cancers and are involved in cell proliferation, angiogenesis, and metastasis.